Tweet
This came to my attention today (ref: http://www.tearscience.com/en/tearsc...es-lipiview-ii)
TearScience Introduces LipiView II
LipiView® II Adds Dynamic Meibomian Imaging to Improve MGD Diagnosis
MORRISVILLE, N.C. ─ September 12, 2014─TearScience®, a privately held medical device company, today announced that the LipiView® II will be introduced during the European Society of Cataract and Refractive Surgery (ESCRS) meeting in London on September 12, 2014. LipiView® II images meibomian glands with Dynamic Meibomian Imaging (DMI) by simultaneously employing novel reflected and transilluminated light sources to provide high definition structural meibomian gland images. The LipiView® II will assist clinicians in improving a patient’s diagnosis of Meibomian Gland Dysfunction (MGD) with objective examination of lipid thickness, blink rate, and meibomian gland structure.
LipiView® II utilizes a novel, patented light-emitting Lid Everter that produces dynamic multi-angle illumination of the Meibomian glands. LipiView® II captures comprehensive information with greater efficiency and allows clinicians to select their preferred meibomian view from one of three modes to analyze gland structure and function as well as use high-resolution images to educate patients on their level of MGD. “When diagnosing MGD, eye care providers must pay attention to both gland function and structure,” said Michel Puech, MD, FRSC, at Explore Vision in Paris, France. “Now with the LipiView® II, we can confidently diagnose MGD taking into account gland structure, blink rate, and lipid layer thickness. The gland images will help us determine which patients will benefit most from the LipiFlow® treatment and communicate the importance of treating the glands before the disease progresses. LipiView® II will prove to be a powerful patient education tool for both me and my staff.”
LipiView® II will be commercially available in Europe during 4Q14 with upgrade options available for current LipiView® owners. The TearScience® Solution for MGD, which includes the LipiView®, Korb Meibomian Gland Evaluator™, and LipiFlow®, allows eye care professionals to safely and effectively identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and causes ocular discomfort. The TearScience® Solution for MGD has been clinically proven to benefit 90 percent of patients. Eye care practices that have implemented LipiView® and LipiFlow® report increased patient satisfaction, an average return on investment of less than 12 months, and improved practice reputation and referrals. TearScience® provides extensive clinical training and support to assist with practice implementation.
About TearScience®
TearScience® is a medical device company that pioneers breakthrough technologies to significantly improve identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD). MGD, the leading cause of dry eye, is chronic and progressive and affects approximately 300 million people worldwide. The TearScience® Solution for MGD is a comprehensive in-office diagnosis and treatment solution that includes the LipiView® Ocular Surface Interferometer, the Korb Meibomian Gland Evaluator™, and the LipiFlow® Thermal Pulsation System. It is FDA-cleared and has been clinically proven to improve outcomes in patients with MGD. For additional information on how TearScience® is improving gland function and alleviating symptoms for patients with MGD worldwide, please visit www.TearScience.com.
Media Contact:
Mary Hecht-Kissell
TearScience®
mhkissell@tearscience.com
(919) 459-4803
TearScience Introduces LipiView II
LipiView® II Adds Dynamic Meibomian Imaging to Improve MGD Diagnosis
MORRISVILLE, N.C. ─ September 12, 2014─TearScience®, a privately held medical device company, today announced that the LipiView® II will be introduced during the European Society of Cataract and Refractive Surgery (ESCRS) meeting in London on September 12, 2014. LipiView® II images meibomian glands with Dynamic Meibomian Imaging (DMI) by simultaneously employing novel reflected and transilluminated light sources to provide high definition structural meibomian gland images. The LipiView® II will assist clinicians in improving a patient’s diagnosis of Meibomian Gland Dysfunction (MGD) with objective examination of lipid thickness, blink rate, and meibomian gland structure.
LipiView® II utilizes a novel, patented light-emitting Lid Everter that produces dynamic multi-angle illumination of the Meibomian glands. LipiView® II captures comprehensive information with greater efficiency and allows clinicians to select their preferred meibomian view from one of three modes to analyze gland structure and function as well as use high-resolution images to educate patients on their level of MGD. “When diagnosing MGD, eye care providers must pay attention to both gland function and structure,” said Michel Puech, MD, FRSC, at Explore Vision in Paris, France. “Now with the LipiView® II, we can confidently diagnose MGD taking into account gland structure, blink rate, and lipid layer thickness. The gland images will help us determine which patients will benefit most from the LipiFlow® treatment and communicate the importance of treating the glands before the disease progresses. LipiView® II will prove to be a powerful patient education tool for both me and my staff.”
LipiView® II will be commercially available in Europe during 4Q14 with upgrade options available for current LipiView® owners. The TearScience® Solution for MGD, which includes the LipiView®, Korb Meibomian Gland Evaluator™, and LipiFlow®, allows eye care professionals to safely and effectively identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and causes ocular discomfort. The TearScience® Solution for MGD has been clinically proven to benefit 90 percent of patients. Eye care practices that have implemented LipiView® and LipiFlow® report increased patient satisfaction, an average return on investment of less than 12 months, and improved practice reputation and referrals. TearScience® provides extensive clinical training and support to assist with practice implementation.
About TearScience®
TearScience® is a medical device company that pioneers breakthrough technologies to significantly improve identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD). MGD, the leading cause of dry eye, is chronic and progressive and affects approximately 300 million people worldwide. The TearScience® Solution for MGD is a comprehensive in-office diagnosis and treatment solution that includes the LipiView® Ocular Surface Interferometer, the Korb Meibomian Gland Evaluator™, and the LipiFlow® Thermal Pulsation System. It is FDA-cleared and has been clinically proven to improve outcomes in patients with MGD. For additional information on how TearScience® is improving gland function and alleviating symptoms for patients with MGD worldwide, please visit www.TearScience.com.
Media Contact:
Mary Hecht-Kissell
TearScience®
mhkissell@tearscience.com
(919) 459-4803
Comment